{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-064669","form_type":"8-K/A","ticker":"TSHA","cik":"0001806310","company_name":"Taysha Gene Therapies, Inc.","filed_at":"2023-03-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.668527+00:00","generated_at":"2026-06-18T08:39:44.837474+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Taysha Gene Therapies finalizes separation with ex-CEO, includes RSU award and board resignation","bullets":["Ex-CEO R.A. Session II resigned from operating role on Dec 16, 2022; severance agreement finalized March 7, 2023.","Severance includes salary continuation for 12 months at his base salary as of separation date.","Also includes COBRA premium payments until Dec 31, 2023 or earlier if new coverage.","Compensation Committee awarded 251,296 vested RSUs replacing a canceled option of 199,500 shares for 2021 performance bonus.","Session also resigned from Board on March 2, 2023, not due to any disagreement."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-064669","json":"https://secwatch.observer/filing/0001193125-23-064669.json","markdown":"https://secwatch.observer/filing/0001193125-23-064669.md","text":"https://secwatch.observer/filing/0001193125-23-064669.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1806310/000119312523064669/0001193125-23-064669-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1806310/000119312523064669/d464178d8ka.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T08:39:44.837474+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4f0b85150b","claim":"R.A. Session II resigned as President and Chief Executive Officer at Taysha Gene Therapies, Inc..","evidence_excerpt":"On December 16, 2022 (the “ Separation Date ”), R.A. Session II, the former President and Chief Executive Officer of the Company, resigned from his operating role, effective immediately.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1806310/000119312523064669/0001193125-23-064669-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"President and Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"669b15275a","claim":"R.A. Session II resigned as Director at Taysha Gene Therapies, Inc..","evidence_excerpt":"On March 2, 2023, Mr. Session notified the Board of his resignation from the Board and all committees thereof effective immediately.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1806310/000119312523064669/0001193125-23-064669-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}